(TSTL) Tristel
Summary
Trade long or short on this share now through an Interactive Investor Spread Bet or CFD
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 4004V Tristel PLC 11 January 2012
TRISTEL plc Director's Shareholding
Tristel plc ("Tristel" or the "Company"), the manufacturer of infection control, contamination control and hygiene products, announces that the Company was informed that Mr Francisco Soler, Non-Executive Chairman, today transferred 263,700 ordinary shares of 1 pence each in the share capital of the Company ("Ordinary Shares") from the Windsor International Corporation account to the World Financial Trading Corp account at a price of 38.25p per share.
Following this transaction Mr Soler and his family's interests total 8,548,877 Ordinary Shares representing 21.38% of the issued share capital of the Company. These interests are held through certain related vehicles as follows:
For further information, please contact:
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 04-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 9613U Tristel PLC 04 January 2012 TRISTEL plc Director's Shareholding
Tristel plc ("Tristel" or the "Company"), the manufacturer of infection control, contamination control and hygiene products, announces that the Company was informed yesterday that Mr Francisco Soler, Non-Executive Chairman, acquired 527,400 Ordinary Shares in the Company on 3 January 2012 at a price of 38.25p per share.
Following this transaction Mr Soler and his family's interests total 8,548,877 Ordinary Shares representing 21.38% of the issued share capital of the Company. These interests are held through certain related vehicles as follows:
For further information, please contact:
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 23-12-11 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 6119U Tristel PLC 23 December 2011 TRISTEL plc Director's Shareholding
Tristel plc ("Tristel" or the "Company"), the manufacturer of infection control, contamination control and hygiene products, announces that the Company was informed on 23 December 2011 that on that date Mr Francisco Soler, Non-Executive Chairman, agreed to acquire 80,000 Ordinary Shares in the Company at a price of 38.0 pence per share. These shares are to be acquired from Mr Paul Swinney, Chief Executive Officer of the Company.
On the same date, Mr Francisco Soler also acquired 20,000 Ordinary Shares in the Company at a price of 39.5 pence per share.
Following this transaction, Mr Swinney will be interested in 1,082,742 Ordinary Shares representing 2.71% of the Company's issued ordinary share capital. Mr Soler and his family's interests total 8,021,477 Ordinary Shares representing 20.06% of the issued share capital of the Company. These interests are held through certain related vehicles as follows:
For further information, please contact:
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 21-12-11 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 4478U Tristel PLC 21 December 2011
TRISTEL plc Grant of Share Options
Tristel plc ("Tristel" or the "Company"), the manufacturer of infection control, contamination control and hygiene consumable products, announces today that Elizabeth Dixon, Finance Director, has been granted options over 10,000 ordinary shares of 1 pence each under the Tristel plc Enterprise Management Incentive Scheme 2005. The share options are exercisable immediately, and for a period of ten years, at 53.75 pence per share.
Following the grant of the options, Elizabeth Dixon now holds 10,000 shares and total options over 130,000 ordinary shares, of which 115,000 are exercisable.
For further information:
About Tristel plc Tristel plc is an infection prevention and contamination control business headquartered in Newmarket, United Kingdom. Its products are used to prevent hospital acquired infections, for hygiene in animal healthcare and by pharmaceutical and personal care manufacturers for contamination control. Its leading brands are Tristel (infection prevention) and Crystel (contamination control). The Group's products are considered to be amongst the highest performing biocides available to healthcare and industry. Tristel's lead technology is a proprietary chlorine dioxide formulation used to disinfect instruments and surfaces and to control legionella and biofilm build up in water.
Tristel was admitted to the London Stock Exchange AIM market in June 2005. Its stock exchange symbol is TSTL.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Tue 10:28 | ||||
|
|
||||
|
|
||||
|
Not familiar with that. What does it have to say?
|
||||
| Mon 23:05 | ||||
|
|
||||
|
|
||||
|
Just flagged up on sharescope datamine. Yes, interested.
J |
||||
| 22-11-11 | ||||
|
|
||||
|
|
||||
|
Largest trading volume yesterday since May. At both dates they appear to be mainly director deals. Is nobody else interested in Tristel any more?
|
||||
| 24-10-11 | ||||
|
|
||||
|
|
||||
|
Hmm, as per my last analysis ( http://www.iii.co.uk/investment/detail/?display=discussion&code=cotn%3ATSTL.L&threshold=0&it=le&action=detail&id=8203289 ) my major problem is still the ongoing dilution. They are spending cash like water, fine (for the company) as long as they can continue to raise cash from equity at reasonable amounts, but I suspect they can only do that trick once more without showing real profitability growth. And not really all that great for existing holders given the large dilution.
With current numbers, the underlying profitability is at 3p eps, which implies a 1.3p dividend, but I don't think they'll make that next year as it implies full upswing in sales and cost controls being tight, and they have consistently disappointed on both fronts there. I would forecast closer to 2p eps (0.9p dividend). The five year forecast of 4p eps is still reasonable (though now one year later), if they break their addiction to spending equity. Not compelling numbers for me, and I suspect the price will drift downward, and that the half year update won't look all that good (after stripping out the R&D relief). This really needs management to get spending under control without affecting growth. I can't see that happening quickly. |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
What's in store today...Editor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
Stock to Watch: Imperial TobaccoEditor's Pick:
George Godber’s AIM stock picks

